Mestag was founded in 2020 by leading investigators and SV Health Investors to develop new medicines for people affected by inflammatory disease and cancer.
Our goal is to bring transformative therapies to patients by targeting activated fibroblast populations and their role in influencing the immune system in disease. The founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology from world-leading institutes in the US and UK including University of Oxford, Harvard Medical School, the Broad Institute, Cold Spring Harbor and Brigham and Women’s Hospital.
We are progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology and are supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company is based in Cambridge, UK.
We are actively assembling a driven, motivated team to discover and develop new therapeutics.
We are hiring! Reach out to learn more about opportunities to join our team.
Our goal is to bring transformative therapies to patients by targeting activated fibroblast populations and their role in influencing the immune system in disease. The founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology from world-leading institutes in the US and UK including University of Oxford, Harvard Medical School, the Broad Institute, Cold Spring Harbor and Brigham and Women’s Hospital.
We are progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology and are supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company is based in Cambridge, UK.
We are actively assembling a driven, motivated team to discover and develop new therapeutics.
We are hiring! Reach out to learn more about opportunities to join our team.
Location: United Kingdom
Employees: 11-50
Total raised: $75.99M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | Sheatrust ... | sheatrustc... |
| - | Forbion | forbion.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.03.2026 | - | $40M | Johnson &a... |
| 28.08.2024 | Grant | $1.98M | - |
| 04.08.2021 | Seed | $34.01M | Forbion |
Mentions in press and media 23
| Date | Title | Description |
| 04.06.2026 | Cambridge Enterprise builds London launchpad for next generation of deeptech founders | A new Cambridge Enterprise Initiative called Leaps is launching today to embed Cambridge-based companies in complementary ecosystems, giving selected founders access to new markets, talent and investment in key geographical hotspots to enab... |
| 04.06.2026 | Cambridge Enterprise launches new initiative to boost Cambridge startups’ access to tech’s biggest global markets | University city ranked behind only the Bay Area and Boston, in Dealroom's latest ranking of global innovation ecosystems. Cambridge, 4 June 2026: A new Cambridge Enterprise Initiative called Leaps is launching today to embed Cambridge-based... |
| 19.05.2026 | Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial | — STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. — Study to evaluate tertiary lymphoid structure (TLS) ... |
| 21.03.2026 | Biotech Powerhouse Mestag Therapeutics Secures $40M for Advanced Therapies | Mestag Therapeutics has secured $40 million in new financing. This pushes its total funding past $95 million. The Cambridge-based biotech fuels its Phase 1 STARLYS clinical trial for cancer drug MST-0312. This pivotal trial begins in mid-20... |
| 17.03.2026 | Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic | -- Financing brings total funds committed to date to >$95 million -- Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline activities in inflammatory di... |
| 17.03.2026 | Mestag Therapeutics: $40 Million Raised To Advance Fibroblast Immunology Cancer Therapies Into Clinic | Mestag Therapeutics, a biotech company focused on fibroblast immunology, has announced the closing of a $40 million financing round, bringing its total funding to more than $95 million. The round was backed by SV Health Investors, Johnson &... |
| 17.03.2026 | Mestag Therapeutics Raises $40M in Financing | Mestag Therapeutics, a Cambridge, UK-based biotech company harnessing fibroblast immunology to develop treatments for cancer and inflammatory diseases, closed a $40m financing. Backers includwed SV Health Investors, Johnson & Johnson, t... |
| 04.03.2025 | Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer | Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, today announced that Matthew Sleeman, PhD, has been appointed Chief Scientific Officer. “Ma... |
| 09.12.2024 | Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform | Cambridge, UK, December 9, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that Johnson & Johnson* has exclusively licensed a novel, undisclosed targe... |
| 09.12.2024 | Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform | Cambridge, UK, December 9, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that Johnson & Johnson* has exclusively licensed a novel, undisclosed targe... |
Show more